Author

Brooke Shankles

Institution: Neoleukin Therapeutics (United States)

Observed institutions: Neoleukin Therapeutics (United States), Seagen (United States)

OpenAlex ID: A5028953362

SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: Evidence of Antitumor Activity from a Phase I Study.

2006 · Ranjana Advani, Andres Forero-Torres, et al. · Blood · 36

509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer

2021 · Aung Naing, Margaret Callahan, et al. · Journal for ImmunoTherapy of Cancer · 4

Works count: 2

Citation count: 40

H-index: 2

I10-index: 1